Study of Circulating Monocytes in Patients With Ischemic Vascular Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUConn Health
About this trial
The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called "P2X4" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries.
The researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
STEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of STEMI.
NSTEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of NSTEMI.
Stable CAD Patients: men and women aged 18 years and older with coronary artery disease proven by prior MI history, angiography or stress test but without any unstable angina or acute coronary syndrome.
Ischemic Stroke Patients: Men and women aged 18 years and over, with symptoms, physical signs and CT/MRI changes characteristic of ischemic stroke.
Disqualifiers
Subjects who are unable to give informed consent (with the exception of the ischemic stroke arm patients, see Protocol Design below) and pregnant subjects.
Subjects who had any history of embolic, ischemic or hemorrhagic stroke within the last 12 months.
Trial population
Recruitment will take place at UConn Health Center. The target populations of 300 will be those with STEMI (60 subjects), NSTEMI (60 subjects) and SCAD (60 subjects), ischemic stroke (60 subjects), and age-matched non-disease subjects (60 subjects). The researchers anticipate that 5% of all recruited subjects will be African American and another 3% will be Latinos and Asians. This represents the distribution of populations recruited in the past for heart disease studies.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
There is no intervention given to the subjects
Other interventionNot appicable
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Hospitalization for Myocardial Infarction, Stroke, or death
myocardial infarction, stroke or death
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov